Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy chinese subjects: An open-label study

Clinical Drug Investigation

Volumn 29, Issue 7, 2009, Pages 451-457

  Chu, Nan Nan ^a   Chen, Wei Li ^a   Xu, Hong Rong ^a   Li, Xue Ning ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HISTAMINE H1 RECEPTOR ANTAGONIST; OLOPATADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REPEATED DRUG DOSE; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, LIQUID; DIBENZOXEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; SEX FACTORS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 67650318487     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/00044011-200929070-00003     Document Type: Article

References (7)

1. Ohmori K, Hayashi KI, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 2002; 88 (2): 379-97
2. Alcon, Inc., Huenenberg. FDA approves olopatadine nasal spray for the treatment of nasal allergy symptoms [online]. Available from http://www.pslgroup.com/dg/21f8fa.htm [Accessed 2008 Apr 16]
3. Tsunoo M, Momomura S, Masuo M, et al. Phase I clinical study on KW-4679, an antiallergic drug - safety and pharmacokinetics in the single and repeated administration study to healthy subjects. Kiso To Rinsho (Clin Report) 1995; 29 (18): 4129-47
4. Ohishi T, Magara H, Yasuzawa T, et al. Disposition of KW-4679 (4): metabolism of KW-4679 in rats and dogs. Xenobiol Metab Dispos 1995; 10 (5): 689-706
5. Tateishi T, Kobayashi S, Shigeyama C, et al. Pharmacokinetics of KW-4679 in the elderly: single-dose and multipledose trials. Drugs Exp Clin Res 1998; 24 (1): 1-7
6. Fujita K, Magara H, Kobayashi H. Determination of olopatadine, a new antiallergic agent, and its metabolites in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. J Chromatogr B 1999; 731 (2): 345-52
7. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharma-cokinet 2002; 41 (5): 329-42